Tailored drug dosing may help stem cell transplant patients recover faster
NCT ID NCT04872595
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This study tests whether giving a personalized dose of a drug called r-ATG before a stem cell transplant can help the immune system recover faster and reduce serious side effects. It includes children and adults with acute leukemia or myelodysplastic syndrome (MDS) receiving a donor stem cell transplant. The goal is to improve survival by better controlling the disease while lowering transplant risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.